Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2025-04-29
2025-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Validation of the Model Predicting Postoperative Delirium Occurrence With Machine Learning-based Analysis of Intraoperative Biological Signals During Anesthesia in Cardiac Surgery
NCT05320965
Effects of Cognitive Intervention Therapy on Postoperative Delirium
NCT06178939
The Incidence and Risk Factors of Postoperative Delirium
NCT04656379
Nitric Oxide Levels Were Associated With Postoperative Delirium Following Cardiac Surgery
NCT06748391
Predictors of Postoperative Delirium in Elder Patients After Spine Surgery: Regional Cerebral Oxygen Saturation
NCT02331953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients aged ≥65 years scheduled for elective noncardiac, non-neurosurgical procedures (e.g., general, orthopedic, urologic, vascular) under general anesthesia with an expected hospital stay ≥2 nights will be included. Exclusion criteria will include dementia, stroke, cerebral tumors, chronic use of antipsychotics or anticholinergics, inability to perform cognitive assessments, or non-English first language.
Data Collection Baseline rSVO₂ Measurement: Baseline rSVO₂ will be measured preoperatively using the O3® Regional Oximetry system (Masimo Corp., Irvine, CA, USA). Sensors will be placed on the patient's forehead while seated, breathing room air, and resting. The stable rSVO₂ value after 60 seconds will be recorded.
Intraoperative rSVO₂ Monitoring: Intraoperative rSVO₂ will be continuously monitored using the same O3® system. Two metrics will be extracted: (1) the absolute lowest intraoperative rSVO₂ value, and (2) the rate of rSVO₂ decrease, calculated as:
$$\\text{rate of rSVO₂ decrease (%)} = \\frac{\\text{Baseline rSVO₂} - \\text{Absolute lowest intraoperative rSVO₂}}{\\text{Baseline rSVO₂}} \\times 100$$
Postoperative Delirium Assessment: POD will be assessed daily for 7 days post-surgery using the Confusion Assessment Method (CAM) \[12\]. A positive CAM on any day will indicate POD.
Postoperative Patient Destination: This will be recorded as transfer to the ICU or general ward post-surgery.
Covariates: These will include age, sex, American Society of Anesthesiologists (ASA) physical status, Charlson Comorbidity Index (CCI), preoperative hemoglobin, frailty, and intraoperative factors: vital signs (mean arterial pressure \[MAP\], heart rate), blood loss (mL), transfusion (yes/no), fluid administration (crystalloid and colloid volumes in mL), and vasopressor use (norepinephrine, phenylephrine, or none). Frailty will be assessed using the Fried Frailty Phenotype, defined by five criteria: unintentional weight loss (\>4.5 kg in the past year), self-reported exhaustion, weak grip strength (measured by dynamometer), slow walking speed (timed 4.5-meter walk), and low physical activity (assessed via patient-reported activity levels) \[16\]. Patients meeting 0 criteria will be classified as robust, 1-2 as pre-frail, and ≥3 as frail. Frailty assessments will be conducted preoperatively by trained study personnel.
Sample Size Calculation
The sample size will be determined to address our primary objective of comparing the predictive performance of three rSVO₂ metrics (baseline rSVO₂, absolute lowest intraoperative rSVO₂, and rate of rSVO₂ decrease) for postoperative delirium (POD) in patients aged ≥65 years. Two complementary approaches will be used:
ROC AUC Comparison: From pilot data, baseline rSVO₂ yielded an AUC of 0.78, while the rate of rSVO₂ decrease had an AUC of 0.70-defining a minimum clinically relevant ΔAUC of 0.08. Using a two-sided α of 0.05, 80% power, and an anticipated POD incidence of 30% (event:non-event ratio ≈0.43:1), investigators will employ the power.roc.test() function in R's pROC package. This analysis indicates that 75 total patients (approximately 22 with POD and 53 without POD) will be sufficient to detect the specified AUC difference.
Multivariable Logistic Regression (EPV Rule): To ensure stable adjustment for covariates in multivariable models, investigators plan to include eight predictors: the three rSVO₂ metrics plus intraoperative blood loss, hypotension, vasopressor use, patient age, and ASA physical status. Applying the "events per variable" rule (minimum 10 events per predictor) will require 80 POD events. Assuming a 30% POD rate, this corresponds to 267 total patients (80 ÷ 0.30).
Finally, to accommodate an anticipated 10% rate of missing data or exclusions, investigators will inflate the larger of these estimates by dividing by 0.90, yielding a target enrollment of 297 patients, which will be rounded to 300 participants.
Statistical Analysis Continuous variables will be reported as mean (SD) or median \[IQR\], and categorical variables as number (%). Normality will be assessed using the Shapiro-Wilk test. Comparisons will use Student's t-test or Mann-Whitney U test for continuous variables and chi-square or Fisher's exact test for categorical variables. Logistic regression models, adjusted for age, ASA status, CCI, hemoglobin, frailty, and intraoperative factors, will evaluate rSVO₂ metrics as predictors of POD. Linear regression will assess factors influencing the rate of rSVO₂ decrease. Pearson correlation and multivariate regression will analyze associations between POD and risk factors. Receiver Operating Characteristic (ROC) curve analysis will compare the predictive accuracy of rSVO₂ metrics. A P-value \<0.05 will be considered significant. Analyses will be performed using SPSS v29.0 (IBM, NY) and R v4.3.0 (R Foundation for Statistical Computing).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wonkwang University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cheol Lee,MD,PhD,
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cheol Lee, M.D.,Ph.D
Role: STUDY_DIRECTOR
Wonkwang University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wonkwang University School of Medicine Hospital
Iksan, Jeollabuk-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhu J, Wang W, Shi H. The Association between Postoperative Cognitive Dysfunction and Cerebral Oximetry during Geriatric Orthopedic Surgery: A Randomized Controlled Study. Biomed Res Int. 2021 Oct 19;2021:5733139. doi: 10.1155/2021/5733139. eCollection 2021.
Schoen J, Meyerrose J, Paarmann H, Heringlake M, Hueppe M, Berger KU. Preoperative regional cerebral oxygen saturation is a predictor of postoperative delirium in on-pump cardiac surgery patients: a prospective observational trial. Crit Care. 2011;15(5):R218. doi: 10.1186/cc10454. Epub 2011 Sep 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Wonkwang UH16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.